TGFBR1 gene silencing attenuates cardiomyopathy in the HFpEF mouse model
PLOS One · 2025
DOI: 10.1371/journal.pone.0328981 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Xuanyang Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. Hauptthemen laut MEDLINE: Gene Silencing, Heart Failure, Cardiomyopathies, Receptors, Transforming Growth Factor beta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Sichuan Medical Association, The Doctoral Start-up Fund of Affiliated Hospital of North Sichuan Medical College.
Abstract (Originalsprache)
Myocardial fibrosis is a principal factor in the progression of heart failure with preserved ejection fraction (HFpEF). Prior research has substantiated the profibrotic impact of transforming growth factor β1. Nevertheless, the function of the transforming growth factor beta receptor (TGFBR) in HFpEF remains uncertain. In this study, we found an increase in myocardial TGFBR1 expression in mice with HFpEF. Silencing of the TGFBR1 gene improved cardiac function in HFpEF mice by attenuating cardiac fibrosis, reducing myocardial hypertrophy, and ameliorating myocardial remodeling. At the mechanistic level, TGFBR1 gene silencing led to a reduction in myocardial collagen synthesis through the Smad2/3 signaling pathway and an inhibition of cardiac hypertrophy through the mitogen-activated protein kinase (MAPK) signaling pathway in HFpEF mice. Additionally, we discovered that TGFBR1 gene silencing mitigated myocardial remodeling in HFpEF mice by suppressing TAK1-mediated PANoptosis, primarily because TGFBR1 gene silencing impeded the dissociation of RIPK1 and TAK1 and reduced Tumor Necrosis Factor Receptor-Associated Factor 6 expression. These findings indicate that TGFBR1 gene silencing enhances cardiac remodeling and function and represents a potential therapeutic target for the treatment of HFpEF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Emergency, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
- Science and Technology Innovation Center of North Sichuan Medical College, Nanchong, China.
- Department of Emergency, Bazhong central hospital, Bazhong, China.
- Department of Clinical Medicine, North Sichuan Medical College, Nanchong, China.
ORCID-Profile: Weidong Li
Förderung
- The Sichuan Medical Association
- The Doctoral Start-up Fund of Affiliated Hospital of North Sichuan Medical College
Zitieren
APA
Shen, X., Li, W., Jiang, X., Wen, H., Shen, Y., Zhang, W., Peng, Y., & Kang, G. (2025). TGFBR1 gene silencing attenuates cardiomyopathy in the HFpEF mouse model. PLOS One. https://doi.org/10.1371/journal.pone.0328981
Vancouver
Shen X, Li W, Jiang X, Wen H, Shen Y, Zhang W, et al. TGFBR1 gene silencing attenuates cardiomyopathy in the HFpEF mouse model. PLOS One. 2025. doi:10.1371/journal.pone.0328981
BibTeX
@article{Shen2025,
author = {Shen, Xuanyang and Li, Weidong and Jiang, Xiaolu and Wen, Hongfu and Shen, Yuan and Zhang, Wen and Peng, Yongjian and Kang, Guoping},
title = {TGFBR1 gene silencing attenuates cardiomyopathy in the HFpEF mouse model},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0328981}
}
EUVIMED